Lyrica (pregabalin) is a small molecule pharmaceutical. Pregabalin was first approved as Lyrica on 2004-07-05. It is used to treat fibromyalgia, postherpetic neuralgia, seizures, and spinal cord injuries in the USA. It has been approved in Europe to treat anxiety disorders, epilepsy, and neuralgia. The pharmaceutical is active against voltage-dependent calcium channel subunit alpha-2/delta-1. In addition, it is known to target voltage-dependent calcium channel subunit alpha-2/delta-2. Lyrica's patent is valid until 2026-11-02 (FDA).
|Indication||anxiety disorders, epilepsy, fibromyalgia, neuralgia, postherpetic neuralgia, seizures, spinal cord injuries|